The Effect of LDL557 on Improving Degenerative Arthritis in the Elderly
Not Applicable
Not yet recruiting
- Conditions
- ArthritisJoint Pain
- Registration Number
- NCT06658821
- Lead Sponsor
- Chung Shan Medical University
- Brief Summary
This project is to conduct a clinical trial of SYNBIO TECH INC.'s LDL557 capsule for joint protection. To understand the improvement of joint discomfort and inflammation after supplementation, we hope to provide an updated choice for modern people's joint protection.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- BMI 18-40 kg/m2;
- Those with early stage degenerative arthritis symptoms judged by X-ray to be Kellgren-Lawrence Grading Scale level 1 or 2, and the physician determines that long-term treatment is not needed or WOMAC score>2.0 or WOMAC total scale score>12 or VAS score ≦3.
Exclusion Criteria
- Smoking
- alcoholism
- diabetes
- breastfeeding women and pregnant women.
- Those consuming dietary supplements were excluded.
- Those who use non-steroidal anti-inflammatory analgesics and those who have had joint surgery.
- Rheumatoid arthritis.
- Those who have had joint injections within 6 months.
- Those with cardiovascular and cerebrovascular, rheumatoid or mental diseases.
- Patients undergoing cancer treatment.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method WOMAC 12 weeks The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is widely used in the evaluation of Hip and Knee Osteoarthritis.
Higher scores indicate worse pain, stiffness, and functional limitations. The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68).
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Chung Shan Medical University
🇨🇳Taichung, Taiwan